Acute Agitation and Dexmedetomidine: A Novel Treatment Approach

<p>In this episode, we delve into a new horizon in the management of acute agitation. We discuss dexmedetomidine, a drug that's been around since 1999, recently reformulated into a sublingual film and FDA approved for treating agitation associated with schizophrenia or bipolar I or II disorder. We explore the results from a recent randomized trial and its potential for transforming psychiatric care.<br /> <br /> Faculty: Jim Phelps, M.D.<br /> Host: Richard Seeber, M.D.</p> <ul> <li><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC253" target="_blank" rel="noopener"><strong>Learn more about our membership here</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-47-2705?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC253" target="_blank" rel="noopener"><strong>Earn 0.5 CMEs: Quick Take Vol. 47</strong></a></li> <li><a href= "https://psychopharmacologyinstitute.com/section/sublingual-dexmedetomidine-for-the-treatment-of-acute-agitation-in-adults-with-schizophrenia-or-schizoaffective-disorder-a-randomized-placebo-controlled-trial-2705-5390?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC253" target="_blank" rel="noopener"><strong>Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial</strong></a></li> </ul>